The Role of TNF-α in the Pathogenesis of Idiopathic Nephrotic Syndrome and Its Usefulness as a Marker of the Disease Course
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Summary
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- International Study of Kidney Disease in Children. Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978, 13, 159–165. [Google Scholar] [CrossRef]
- KDIGO Clinical Practice Guideline for Glomerulonephritis. Available online: https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf (accessed on 12 December 2023).
- Lombel, R.M.; Gipson, D.S.; Hodson, E.M. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: New guidelines from KDIGO. Pediatr. Nephrol. 2013, 28, 415–426. [Google Scholar] [CrossRef]
- Mendonça, A.C.; Oliveira, E.A.; Fróes, B.P.; Faria, L.D.; Pinto, J.S.; Nogueira, M.M.; Lima, G.O.; Resende, P.I.; Assis, N.S.; Simões E Silva, A.C.; et al. A predictive model of progressive chronic kidney disease in idiopathic nephrotic syndrome. Pediatr. Nephrol. 2015, 30, 2011–2020. [Google Scholar] [CrossRef]
- Garin, E.H.; West, L.; Zheng, W. Effect of interleukin-8 on glomerular sulfated compounds and albuminuria. Pediatr. Nephrol. 1997, 11, 274–279. [Google Scholar] [CrossRef]
- Souto, M.F.; Teixeira, A.L.; Russo, R.C.; Penido, M.G.; Silveira, K.D.; Teixeira, M.M.; Simões E Silva, A.C. Immune mediators in idiopathic nephrotic syndrome: Evidence for a relation between interleukin 8 and proteinuria. Pediatr. Res. 2008, 64, 637–642. [Google Scholar] [CrossRef]
- Lai, K.W.; Wei, C.L.; Tan, L.K.; Tan, P.H.; Chiang, G.S.; Lee, C.G.; Jordan, S.C.; Yap, H.K. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J. Am. Soc. Nephrol. 2007, 18, 1476–1485. [Google Scholar] [CrossRef]
- Zheng, Y.; Hou, L.; Wang, X.L.; Zhao, C.G.; Du, Y. A review of nephrotic syndrome and atopic diseases in children. Transl. Androl. Urol. 2021, 10, 475–482. [Google Scholar] [CrossRef]
- Ahmadian, E.; Rahbar, S.Y.; Dalir, A.E.; Bastami, M.; Shoja, M.M.; Zununi, V.S.; Ardalan, M. The Role of Cytokines in Nephrotic Syndrome. Mediat. Inflamm. 2022, 9, 6499668. [Google Scholar] [CrossRef]
- Reiser, J.; Mundel, P. Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome. J. Am. Soc. Nephrol. 2004, 15, 2246–2248. [Google Scholar] [CrossRef] [PubMed]
- Shimada, M.; Araya, C.; Rivard, C.; Ishimoto, T.; Johnson, R.J.; Garin, E.H. Minimal change disease: A “two-hit” podocyte immune disorder? Pediatr. Nephrol. 2011, 26, 645–649. [Google Scholar] [CrossRef] [PubMed]
- Davin, J.C. The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr. Nephrol. 2016, 31, 207–215. [Google Scholar] [CrossRef]
- Liang, Y.; Chen, Y.; Chen, Y.; Gong, Y. Role of the glucocorticoid receptor in the recurrence of primary nephrotic syndrome. Exp. Ther. Med. 2015, 10, 1556–1562. [Google Scholar] [CrossRef]
- Li, X.; Qi, D.; Wang, M.-Y.; Ji, K.; Xie, Q.-L.; Wang, Y.; Du, S.-H.; Fan, H.-Y. Salvianolic acid A attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-αvβ3 signaling inhibition. J. Ethnopharmacol. 2021, 279, 114351. [Google Scholar] [CrossRef]
- Wei, C.; Trachtman, H.; Li, J.; Dong, C.; Friedman, A.L.; Gassman, J.J.; McMahan, J.L.; Radeva, M.; Heil, K.M.; Trautmann, A.; et al. PodoNet and FSGS CT Study Consortia. Circulating suPAR in Two Cohorts of Primary FSGS. J. Am. Soc. Nephrol. 2012, 23, 2051–2059. [Google Scholar] [CrossRef]
- Li, F.; Zheng, C.; Zhong, Y.; Zeng, C.; Xu, F.; Yin, R.; Jiang, Q.; Zhou, M.; Liu, Z. Relationship between Serum Soluble Urokinase Plasminogen Activator Receptor Level and Steroid Responsiveness in FSGS. Clin. J. Am. Soc. Nephrol. 2014, 9, 1903–1911. [Google Scholar] [CrossRef]
- Wada, T.; Nangaku, M. A circulating permeability factor in focal segmental glomerulosclerosis: The hunt continues. Clin. Kidney J. 2015, 8, 708–715. [Google Scholar] [CrossRef] [PubMed]
- Cara-Fuentes, G.; Wei, C.; Segarra, A.; Ishimoto, T.; Rivard, C.; Johnson, R.J.; Reiser, J.; Garin, E.H. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: Diagnostic and pathogenic significance. Pediatr. Nephrol. 2014, 29, 1363–1371. [Google Scholar] [CrossRef] [PubMed]
- Pukajło-Marczyk, A.; Zwolińska, D. Involvement of Hemopexin in the Pathogenesis of Proteinuria in Children with Idiopathic Nephrotic Syndrome. J. Clin. Med. 2021, 10, 3160. [Google Scholar] [CrossRef] [PubMed]
- Pukajło-Marczyk, A.; Zwolińska, D. The role of IL-13 in the pathogenesis of idiopathic nephrotic syndrome (INS) in children. Fam. Med. Prim. Care Rev. 2016, 2, 149–154. [Google Scholar] [CrossRef]
- Holbrook, J.; Lara-Reyna, S.; Jarosz-Griffiths, H.; McDermott, M. Tumour necrosis factor signalling in health and disease. F1000Research 2019, 8, 111. [Google Scholar] [CrossRef]
- You, K.; Gu, H.; Yuan, Z.; Xu, X. Tumor Necrosis Factor Alpha Signaling and Organogenesis. Front. Cell Dev. Biol. 2021, 30, 727075. [Google Scholar] [CrossRef] [PubMed]
- Tolide-ie, H.; Tabatabaee, H.R.; Kamali-Sarvestani, E. Association between Tumor Necrosis Factor-α-308 G/A Polymorphism and Multiple Sclerosis: A Systematic Review and Meta-Analysis. Iran. J. Med. Sci. 2014, 39, 2–10. [Google Scholar] [PubMed]
- Toussi, S.S.; Pan, N.; Walters, H.M.; Walsh, T.J. Infections in Children and Adolescents with Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Treated with Tumor Necrosis Factor–α Inhibitors: Systematic Review of the Literature. Clin Infect Dis. 2013, 57, 1318–1330. [Google Scholar] [CrossRef]
- Roman, D.; Iurciuc, S.; Caraba, A. Pulmonary Involvement in Sjögren’s Syndrome: Correlations with Biomarkers of Activity and High-Resolution Computer Tomography Findings. J. Clin. Med. 2024, 13, 1100. [Google Scholar] [CrossRef]
- Combe, B.; Allanore, Y.; Alten, R.; Caporali, R.; Durez, P.; Iannone, F.; Nurmohamed, M.T.; Toumi, M.; Lee, S.J.; Kwon, T.S.; et al. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: A network meta-regression of individual patient data from two randomised trials. Arthritis Res. Ther. 2021, 23, 119. [Google Scholar] [CrossRef]
- Ditto, M.C.; Parisi, S.; Cotugno, V.; Barila, D.A.; Lo Sardo, L.; Cattel, F.; Fusaro, E. Subcutaneous infliximab CT-P13 without intravenous induction in psoriatic arthritis: A case report and pharmacokinetic considerations. Int. J. Clin. Pharmacol. Ther. 2024, 62, 122–125. [Google Scholar] [CrossRef] [PubMed]
- Bertani, T.; Abbate, M.; Zoja, C.; Corna, D.; Perico, N.; Ghezzi, P.; Remuzzi, G. Tumor necrosis factor induces glomerular damage in the rabbit. Am. J. Pathol. 1989, 134, 419–430. [Google Scholar]
- Takemura, T.; Yoshioka, K.; Murakami, K.; Akano, N.; Okada, M.; Aya, N.; Maki, S. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch. 1994, 424, 459–464. [Google Scholar] [CrossRef]
- Wan, Q.; Zhou, J.; Wu, Y.; Shi, L.; Liu, W.; Ou, J.; Gao, J. TNF-α-mediated podocyte injury via the apoptotic death receptor pathway in a mouse model of IgA nephropathy. Ren. Fail. 2022, 44, 1216–1226. [Google Scholar] [CrossRef]
- Huang, Y.S.; Fu, S.H.; Lu, K.C.; Chen, J.S.; Hsieh, H.Y.; Sytwu, H.K.; Wu, C.C. Inhibition of tumor necrosis factor signaling attenuates renal immune cell infiltration in experimental membranous nephropathy. Oncotarget 2017, 8, 111631–111641. [Google Scholar] [CrossRef]
- Gómez-Chiarri, M.; Ortíz, A.; Lerma, J.L.; López-Armada, M.J.; Mampaso, F.; González, E.; Egido, J. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab. Investig. 1994, 70, 449–459. [Google Scholar]
- International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int. 1981, 20, 765–771. [Google Scholar] [CrossRef]
- Schwartz, G.J.; Muñoz, A.; Schneider, M.F.; Mak, R.H.; Kaskel, F.; Warady, B.A.; Furth, S.L. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol. 2009, 20, 629–637. [Google Scholar] [CrossRef]
- Cho, M.H.; Lee, H.S.; Choe, B.H.; Kwon, S.H.; Chung, K.Y.; Koo, J.H.; Ko, C.W. Interleukin-8 and tumor necrosis factor-alpha are increased in minimal change disease but do not alter albumin permeability. Am. J. Nephrol. 2003, 23, 260–266. [Google Scholar] [CrossRef]
- Laflam, P.F.; Garin, E.H. Effect of tumor necrosis factor alpha and vascular permeability growth factor on albuminuria in rats. Pediatr. Nephrol. 2006, 21, 177–181. [Google Scholar] [CrossRef]
- Lama, G.; Luongo, I.; Tirino, G.; Borriello, A.; Carangio, C.; Salsano, M.E. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am. J. Kidney Dis. 2002, 39, 958–965. [Google Scholar] [CrossRef]
- Bustos, C.; González, E.; Muley, R.; Alonso, J.L.; Egido, J. Increase of tumour necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur. J. Clin. Investig. 1994, 24, 799–805. [Google Scholar] [CrossRef] [PubMed]
- Weissbach, A.; Garty, B.Z.; Lagovsky, I.; Krause, I.; Davidovits, M. Serum Tumor Necrosis Factor-Alpha Levels in Children with Nephrotic Syndrome: A Pilot Study. Isr. Med. Assoc. J. 2017, 19, 30–33. [Google Scholar] [PubMed]
- Roca, N.; Martinez, C.; Jatem, E.; Madrid, A.; Lopez, M.; Segarra, A. Activation of the acute inflammatory phase response in idiopathic nephrotic syndrome: Association with clinicopathological phenotypes and with response to corticosteroids. Clin. Kidney J. 2021, 14, 1207–1215. [Google Scholar] [CrossRef]
- Daniel, V.; Trautmann, Y.; Konrad, M.; Nayir, A.; Schärer, K. T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin. Nephrol. 1997, 47, 289–297. [Google Scholar]
- Rizk, M.K.; El-Nawawy, A.; Abdel-Kareem, E.; Amer, E.S.; El-Gezairy, D.; El-Shafei, A.Z. Serum interleukins and urinary microglobulin in children with idiopathic nephrotic syndrome. East. Mediterr. Health J. 2005, 11, 993–1002. [Google Scholar] [PubMed]
Biochemical Parameters | ||||
---|---|---|---|---|
Groups | Serum Albumin [g/dL] | Total Cholesterol [mg/dL] | Protein/Creatinine Ratio [g Protein/g Creatinine] | CRP [mg/L] |
Total INS N = 51 | 1.90 (1.05–2.55) | 363.0 (268.0–475.0) | 6.2 (3.0–10.6) | 2.90 (0.80–3.60) |
Group IA N = 20 | 1.70 (1.40–2.20) | 372.0 (297.0–464.0) | 4.85 (2.40–7.90) | 1.75 (0.40–3.60) |
Group IB N = 31 | 2.40 (1.00–3.10) | 329.5 (238.0–601.0) | 7.0 (3.9–10.7) | 3.10 (1.65–3.69) |
Group IIA N = 26 | 1.90 (1.10–2.50) | 366.5 (286.5–442.5) | 4.71 (2.5–7.76) a | 3.30 (1.40–3.60) |
Group IIB N = 22 | 2.0 (1.00–2.50) | 329.5 (264.0–636.0) | 9.6 (6.2–19.2) | 2.56 (1.60–4.20) |
Groups | |||
---|---|---|---|
Parameters | Whole Group INS Relapse N = 51 | Whole Group INS Remission N = 35 | Control N = 18 |
sTNF-α [pg/mL] | 45.4 (43.8–47.4) a,b | 17.5 (15.6–18.8) a | 13.2 (12.6–13.6) |
uTNF-α [pg/mL] | 6.24 (5.50–7.10) a,b | 2.06 (1.81–2.56) a | 1.28 (1.23–1.33) |
Group | ||||
---|---|---|---|---|
Parameter | IA Relapse N = 20 | IB Relapse N = 31 | IA Remission N = 9 | IB Remission N = 26 |
sTNF-á [pg/mL] | 45.1 (43.7–46.8) | 45.6 (43.9–48.2) | 15.2 a (13.9–17.3) | 17.7 (16.1–19.1) |
uTNF-á [pg/mL] | 6.27 (5.84–6.73) | 6.24 (5.41–7.10) | 2.55 (2.06–2.55) | 2.06 (1.81–2.56) |
Groups | ||||
---|---|---|---|---|
Parameters | IIA Relapse N = 26 | IIB Relapse N = 22 | IIA Remission N = 17 | IIB Remision N = 17 |
sTNF-α [pg/mL] | 44.6 (43.6–46.8) | 46.0 (44.8–48.4) | 17.5 (15.6–19.1) | 17.5 (15.9–18.4) |
uTNF-α [pg/mL] | 6.32 (5.50–7.10) | 6.20 (5.50–6.67) | 2.06 (1.56–2.55) | 2.06 (1.92–2.56) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pukajło-Marczyk, A.; Zwolińska, D. The Role of TNF-α in the Pathogenesis of Idiopathic Nephrotic Syndrome and Its Usefulness as a Marker of the Disease Course. J. Clin. Med. 2024, 13, 1888. https://doi.org/10.3390/jcm13071888
Pukajło-Marczyk A, Zwolińska D. The Role of TNF-α in the Pathogenesis of Idiopathic Nephrotic Syndrome and Its Usefulness as a Marker of the Disease Course. Journal of Clinical Medicine. 2024; 13(7):1888. https://doi.org/10.3390/jcm13071888
Chicago/Turabian StylePukajło-Marczyk, Agnieszka, and Danuta Zwolińska. 2024. "The Role of TNF-α in the Pathogenesis of Idiopathic Nephrotic Syndrome and Its Usefulness as a Marker of the Disease Course" Journal of Clinical Medicine 13, no. 7: 1888. https://doi.org/10.3390/jcm13071888